Literature DB >> 3797365

Levodopa withdrawal syndrome identical to neuroleptic malignant syndrome.

W R Gibb, D N Griffith.   

Abstract

A 60 year old woman with idiopathic Parkinson's disease had been prescribed thioridazine for schizophrenia. Five months after this was stopped, Sinemet also considered of dubious therapeutic value, was withdrawn. One week later she developed features of the neuroleptic malignant syndrome (NMS) accompanied by myoglobinuric renal failure. Post-mortem examination confirmed Lewy body degeneration in the substantia nigra. It is proposed that NMS may be caused by levodopa withdrawal in Parkinson's disease, and that it is withdrawal of dopaminergic drive that causes the syndrome.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3797365      PMCID: PMC2418564          DOI: 10.1136/pgmj.62.723.59

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  6 in total

1.  Fatal hyperpyrexia after withdrawal of levodopa.

Authors:  G P Sechi; F Tanda; R Mutani
Journal:  Neurology       Date:  1984-02       Impact factor: 9.910

2.  [Neuroleptic malignant syndrome. Beneficial effects of dantrolene on hyperthermia and hypertonia (author's transl)].

Authors:  P de Rohan Chabot; D Elkharrat; F Conso; C Bismuth; M Goulon
Journal:  Nouv Presse Med       Date:  1982-03-27

3.  Neuroleptic malignant syndrome: a pathogenetic role for dopamine receptor blockade?

Authors:  V W Henderson; G F Wooten
Journal:  Neurology       Date:  1981-02       Impact factor: 9.910

4.  Neuroleptic malignant syndrome-like state following a withdrawal of antiparkinsonian drugs.

Authors:  M Toru; O Matsuda; K Makiguchi; K Sugano
Journal:  J Nerv Ment Dis       Date:  1981-05       Impact factor: 2.254

5.  Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease.

Authors:  R E Burke; S Fahn; R Mayeux; H Weinberg; K Louis; J H Willner
Journal:  Neurology       Date:  1981-08       Impact factor: 9.910

6.  The hypothalamus in Parkinson disease.

Authors:  J W Langston; L S Forno
Journal:  Ann Neurol       Date:  1978-02       Impact factor: 10.422

  6 in total
  11 in total

1.  Efficacy of methylprednisolone pulse therapy on neuroleptic malignant syndrome in Parkinson's disease.

Authors:  Y Sato; T Asoh; N Metoki; K Satoh
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-05       Impact factor: 10.154

2.  Case files of the program in medical toxicology at brown university: amantadine withdrawal and the neuroleptic malignant syndrome.

Authors:  Eric Brantley; Jamieson Cohn; Kavita Babu
Journal:  J Med Toxicol       Date:  2009-06

Review 3.  Parkinson's disease.

Authors:  E C Wolters; D B Calne
Journal:  CMAJ       Date:  1989-03-01       Impact factor: 8.262

4.  Levodopa withdrawal and the neuroleptic malignant syndrome.

Authors:  R Sandyk; R P Iacono
Journal:  Postgrad Med J       Date:  1986-07       Impact factor: 2.401

Review 5.  Medication management on sick days.

Authors:  Tom N Lea-Henry; Jonathan Baird-Gunning; Elizabeth Petzel; Darren M Roberts
Journal:  Aust Prescr       Date:  2017-10-03

Review 6.  Clinical management of neuroleptic malignant syndrome.

Authors:  V L Susman
Journal:  Psychiatr Q       Date:  2001

7.  Emergency treatment of movement disorders.

Authors:  Shu-Ching Hu; Steven J Frucht
Journal:  Curr Treat Options Neurol       Date:  2007-03       Impact factor: 3.598

Review 8.  Aetiology and treatment of neuroleptic malignant syndrome.

Authors:  C Harpe; A Stoudemire
Journal:  Med Toxicol       Date:  1987 May-Jun

Review 9.  Bench-to-bedside review: Rhabdomyolysis -- an overview for clinicians.

Authors:  Ana L Huerta-Alardín; Joseph Varon; Paul E Marik
Journal:  Crit Care       Date:  2004-10-20       Impact factor: 9.097

Review 10.  Implications of dopaminergic medication withdrawal in Parkinson's disease.

Authors:  J Koschel; K Ray Chaudhuri; L Tönges; M Thiel; V Raeder; W H Jost
Journal:  J Neural Transm (Vienna)       Date:  2021-07-29       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.